Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 248 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pruritus Clear all
Completed Not applicable Interventional

Bleach Bath Treatment of Adults With Atopic Dermatitis

NCT01996150
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
bleach bath (sodium hypochlorite)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 3 Interventional

Gabapentin to Treat Itch in Patients With Liver Disease

NCT00058890
View directory record Official record
Conditions
Liver Disease, Cholestasis, Cirrhosis, Pruritus, Itching
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jul 22, 2026, 5:49 AM EDT
Terminated Phase 4 Interventional Results available

Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

NCT03262038
View directory record Official record
Conditions
Pruritus, Nausea/Vomiting
Interventions
Ondansetron, Placebo Comparator
Drug
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Jul 22, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

NCT02975271
View directory record Official record
Conditions
Pruritus, Burns
Interventions
Serlopitant, Placebo
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Jul 22, 2026, 5:49 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis

NCT06488742
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus
Interventions
3% kanuka oil
Other
Lead sponsor
Nexgen Dermatologics, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Jul 22, 2026, 5:49 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

NCT06736262
View directory record Official record
Conditions
Urticaria Chronic
Interventions
Briquilimab
Drug
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 22, 2026, 5:49 AM EDT
Not listed Not applicable Interventional

Hypnosis for Pain and Itch Following Burn Injuries

NCT01828541
View directory record Official record
Conditions
Burns
Interventions
Hypnosis, Standard of Care
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Jul 22, 2026, 5:49 AM EDT
Withdrawn No phase listed Observational

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

NCT01801670
View directory record Official record
Conditions
Pruritus
Interventions
Biopsy, Blood
Procedure
Lead sponsor
Boston University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

NCT03721172
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
43
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients

NCT00693654
View directory record Official record
Conditions
Pruritis
Interventions
Sarna, Cetaphil
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 22, 2026, 5:49 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT07205081
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Interventions
ATTO-3712, Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Encinitas, California • Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

NCT03448081
View directory record Official record
Conditions
Pruritus, Psoriasis
Interventions
SNA-120, Placebo, Calcipotriene
Drug
Lead sponsor
Sienna Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
17
States / cities
Anniston, Alabama • Mobile, Alabama • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function

NCT02268448
View directory record Official record
Conditions
Cutaneous Nerves CNS Itch
Interventions
Clonidine, Naltrexone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

NCT01976364
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Tofacitinib, Methotrexate, Placebo Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

NCT03553823
View directory record Official record
Conditions
Chronic Plaque-type Psoriasis
Interventions
Skin biopsies
Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
New Orleans, Louisiana • East Windsor, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jul 22, 2026, 5:49 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

NCT05493488
View directory record Official record
Conditions
Tinea Pedis
Interventions
DBI-001 Gel, DBI-002 Gel, Aqueous Gel
Biological
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Portland, Oregon • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Jul 22, 2026, 5:49 AM EDT
Terminated Phase 3 Interventional

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

NCT02811783
View directory record Official record
Conditions
Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Sézary Syndrome
Interventions
Naloxone Hydrochloride Lotion, 0.5%, Placebo Lotion
Drug
Lead sponsor
Elorac, Inc.
Industry
Eligibility
21 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Little Rock, Arkansas • Duarte, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients

NCT01114672
View directory record Official record
Conditions
Pruritis
Interventions
50,000 Units Ergocalciferol, Placebo
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Bethpage, New York • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

NCT03011892
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD, Ruxolitinib 1.5% Cream BID, Triamcinolone 0.1% Cream BID, Vehicle Cream BID
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Birmingham, Alabama • Bryant, Arkansas • Encino, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

NCT01806597
View directory record Official record
Conditions
Moderate to Severe Palmoplantar Psoriasis
Interventions
secukinumab 150 mg, secukinumab 300 mg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03281538
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Chula Vista, California • El Centro, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

NCT03858634
View directory record Official record
Conditions
Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
Interventions
KPL-716, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 22, 2026, 5:49 AM EDT
Completed Not applicable Interventional

A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area

NCT05226143
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Gel Cream
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jul 22, 2026, 5:49 AM EDT